国产重组人白介素-11治疗恶性肿瘤化疗后血小板减少疗效观察要点构架

The Main Point of Observation of the Efficacy of Domestic Recombinant Human Interleukin-11 in the Treatment of Thrombocytopenia after Chemotherapy

目的探究国产重组人白介素-11对恶性肿瘤化疗后血小板减少的治疗效果。方法方便选取2016年12月—2018年12月期间收治的80例恶性肿瘤化疗后血小板减少患者,以随机数字表法将其分入对照组(40例)和研究组(40例)。对照组使用重组人血小板生成素,研究组使用国产重组人白介素-11。比较治疗前、后两组的血小板计数以及不良反应发生率。结果治疗前,研究组、对照组的血小板计数分别为(24.87±1.11)×109/L、(24.83±1.15)×109/L,两组相比,差异无统计学意义(t=0.158,P=0.875>0.05)。治疗后,研究组、对照组的血小板计数分别为(223.69±11.93)×109/L、(163.67±10.80)×109/L,两组患者的血小板计数较治疗前有了明显改变且研究组的血小板计数高于对照组,差异有统计学意义(t=23.589,P=0.000<0.05)。研究组不良反应发生率为10.00%,低于对照组30.00%的不良反应发生率,均差异有统计学意义(χ2=5.000,P=0.025<0.05)。结论国产重组人白介素-11对恶性肿瘤化疗后血小板减少有显著疗效与安全性。

Objective To investigate the therapeutic effect of domestic recombinant human interleukin-11 on thrombocytopenia after chemotherapy in malignant tumors.Methods Eighty patients with thrombocytopenia after chemotherapy from December 2016 to December 2018 were convenient enrolled.The patients were divided into the control group(40 cases)and the study group(40 cases)by random number table method.Recombinant human thrombopoietin was used in the control group,and the recombinant human interleukin-11 was used in the study group.The platelet count and the incidence of adverse reactions were compared between the two groups before and after treatment.Results Before treatment,the platelet counts of the study group and the control group were(24.87±1.11)×109/L,(24.83±1.15)×109/L,respectively.There was no significant difference between the two groups(t=0.158,P=0.875>0.05).After treatment,the platelet counts of the study group and the control group were(223.69±11.93)×109/L,(163.67±10.80)×109/L,respectively.The platelet count of patients in the two groups was significantly different from that before treatment,and the platelet count in the study group was higher than that in the control group,with statistically significant difference(t=23.589,P=0.000<0.05).The incidence of adverse reactions in the study group was 10.00%,which was lower than that in the control group(30.00%).The difference was statistically significant(χ2=5.000,P=0.025<0.05).Conclusion Domestic recombinant human interleukin-11 has significant efficacy and safety in the treatment of thrombocytopenia after chemotherapy.